Indivior Pharmaceuticals, Inc. has announced the declaration of a special cash dividend as part of its agreement to merge with Supernus Pharmaceuticals, Inc. The dividend is set at $8.13 per share of Indivior common stock. The payment is contingent upon the successful closing of the merger transaction.
Shareholders of record as of October 30, 2026, will be eligible to receive the dividend. The company also stated that the dividend will be payable to holders of certain Indivior equity awards outstanding on the record date, contingent upon the vesting of those awards.
The payment of the dividend is subject to the consummation of the merger, which is expected to occur on or about November 2, 2026. If the merger closes as anticipated, the dividend is expected to be paid to eligible record holders on or about November 6, 2026. Indivior noted that Supernus stockholders will not be entitled to receive the dividend with respect to any Indivior common stock received as merger consideration.
The company also provided a tax note indicating that for U.S. holders, the dividend will be treated first as a return of capital to the extent of the holder's basis in the stock and then as capital gain.
